OrsoBio Announces Phase 1 Trial of TLC-6740, a Mitochondrial Protonophore for the Treatment of Obesity and Associated Diseases

PALO ALTO, Calif.–(BUSINESS WIRE)– OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced completion of the second cohort of subjects in an ongoing Phase 1 trial of TLC-6740, a liver-targeted mitochondrial protonophore. The first-in-human, Phase 1 study is exploring the safety and efficacy of TLC-6740 as an oral, first-in-class, liver-targeted […]

OrsoBio Announces First Patient Dosed in Phase 2 Clinical Trial of the ACC2 Inhibitor TLC-3595, a Potential Treatment for Type 2 Diabetes

— Trial will evaluate the insulin-sensitizing effects of TLC-3595, alone and in combination with approved diabetes therapies — PALO ALTO, Calif.–(BUSINESS WIRE)–OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced that the first patient has been dosed in a Phase 2a clinical trial evaluating TLC-3595, a selective inhibitor of acetyl-CoA carboxylase […]

OrsoBio Announces Presentation of Five Abstracts at AASLD’s The Liver Meeting® 2022 Highlighting Programs for Severe Metabolic Disorders

— Company to share clinical and preclinical data on ACC2, LXR, mitochondrial protonophore, and ACMSD programs — OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced the presentation of five abstracts from the company’s programs at AASLD’s The Liver Meeting® from November 4-8. OrsoBio recently announced that it has acquired novel […]